Areas of Interest
Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Neoplasms; Leukemia Clinical Trials; Immunotherapies for Leukemias
Matthew Foster, MD, specializes in the diagnosis and management leukemia and related bone marrow cancers, including Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (including Chronic Myeloid Leukemia). Foster is particularly interested in improving care for acute leukemias through shared decision-making with his patients and providing them access to clinical trials. An active focus of Foster and the Leukemia Program is to partner with blood and molecular pathologists to provide rapid and accurate characterization of leukemias as well as response to treatments. This unique partnership allows patients to have timely access to state-of-the art treatments for their leukemias.
Foster is the principal investigator for many leukemia clinical trials at UNC. Because of a strong belief in team science, he collaborates with research and advocacy groups both within and outside of UNC. At UNC, he conducts research into leukemia treatments in both the leukemia clinical trials group and cellular immunotherapy program. Within the immunotherapy program, he is PI of LCCC 1541 (NCT03016377)—a phase I/II trial evaluating the use of chimeric antigen receptor modified T cells (CAR-T cells) with a novel safety switch in patients with B-cell ALL. This trial aims to improve the management of CAR-T cell toxicities. Research involving novel tests for diagnosing leukemia and predicting outcomes is done through the Office of Clinical and Translational Research. Other internal collaborations involve improving care for adolescents and young adults (AYAs) with leukemias through the UNC AYA program, and research aimed at improving quality of life for leukemia patients with colleagues in the Leukemia Program and the School of Nursing. Outside of UNC, Foster is an investigator within the Alliance for Clinical Trials in Oncology, the Beat AML consortium sponsored by the Leukemia and Lymphoma Society, and serves as co-PI for UNC’s MDS Foundation Center of Excellence. Additionally, he serves as investigator for several trials sponsored by industry partners.
Education and Training
- Undergraduate University of North Carolina at Chapel Hill
- Medical School University of North Carolina School of Medicine
- Residency University of North Carolina Hospitals
- Fellowship University of North Carolina Hospitals